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STOMACH
Mortality study of 18 000 patients treated with
omeprazole
D N Bateman, D Colin-Jones, S Hartz, M Langman, R F Logan, J Mant, M Murphy,
K R Paterson, R Rowsell, S Thomas, M Vessey, for the SURVEIL (Study of Undetected
Reactions. Vigilance Enquiry into Links) Group
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Gut 2003;52:942–946
Background: The long term safety of potent gastric acid suppressive therapy has yet to be established.
Method: General practice record review at a median interval of 26 months followed by retrieval of
details of all deaths within four years using the UK National Health Service Central Registers in 17 936
patients prescribed omeprazole in 1993–1995. Death rates were compared with general population
rates.
Results: Records of 17 489 patients (97.5%) were examined. A total of 12 703 patients received fur-
ther scripts for antisecretory drugs, 8097 for omeprazole only (65.6%): 3097 patients have died. All
cause mortality was higher in the first year (observed/expected (O/E) 1.44 (95% confidence intervals
(CI) 1.34–1.55); p<0.0001) but had fallen to population expectation by the fourth year. There were
significant mortality increases in the first year, falling to or below population expectation by the fourth
year, for deaths ascribed to neoplasms (1.82 (95% CI 1.58–2.08); p<0.0001), circulatory diseases
(1.27 (95% CI 1.13–1.43); p<0.0001), and respiratory diseases (1.37 (95% CI 1.12–1.64);
p<0.001). Increased mortality ascribed to digestive diseases (2.56 (95% CI 1.87–3.43); p<0.0001)
persisted, although reduced. Increased mortality rates for cancers of the stomach (4.06 (95% CI 2.60–
6.04); p<0.0001), colon and rectum (1.40 (95% CI 0.84–2.18); p=0.075), and trachea, bronchus,
and lung (1.64 (95% CI 1.19–2.19); p<0.01) seen in the first year had disappeared by the fourth year
but that for cancer of the oesophagus had not (O/E 7.35 (95% CI 5.20–10.09) (p<0.0001) in year
1; 2.88 (95% CI 1.62–4.79) (p<0.001) in year 4). Forty of 78 patients dying of oesophageal cancer
had the disease present at registration. Twenty seven of those remaining cases had clinical evidence of
Barrett’s disease, stricture, ulcer, or oesophagitis at registration (O/E 3.30 (95% CI 2.17–4.80)). Six
deaths occurred in patients with hiatal hernia or reflux only (O/E 1.02 (95% CI 0.37–2.22)) and five
in patients without oesophageal disease (O/E 0.77 (95% CI 0.25–1.80)). No relationships were
detected with numbers of omeprazole scripts received.
Conclusions: Increases in mortality associated with treatment are due to pre- existing illness, includ-
ing pre-existing severe oesophageal disease. There was no evidence of an increased risk of oesopha-
geal adenocarcinoma in those without oesophageal mucosal damage recorded at registration.
The introduction of any new class of drugs, such as theproton pump inhibitors (PPIs), where usage is likely to bewidespread and prolonged, requires that safety during
chronic treatment is assured. The need for such assessment is
emphasised by claims that omeprazole treatment might
adversely affect the management of upper gastrointestinal
cancer because amelioration of symptoms and re-
epithelialisation of the cancer might be promoted, so hinder-
ing disease recognition.1 It has also been suggested that raised
serum gastrin concentrations in response to reduced acidity
might act as growth promoters,2 or that treatment might
accelerate the onset of atrophic gastritis, so predisposing to
gastric cancer.3 Moreover, as omeprazole is commonly used to
treat gastro-oesophageal reflux disease, it is important to
determine whether treatment influences the frequency of
oesophageal adenocarcinoma, a tumour known to complicate
oesophageal metaplasia (Barrett’s disease), which occurs in
association with oesophageal reflux associated damage.
We examined mortality rates from any cause over a four
year period during or after treatment with omeprazole in six
cities in England and Scotland. Death rates were compared
with those expected nationally. Data have strength in relating
risks to those observed in the general population, as done pre-
viously by us for cimetidine.4–6
METHOD
We sought to register a cohort of 18 000 patients prescribed
omeprazole in the six UK conurbations of or surrounding Bir-
mingham, Glasgow, Newcastle, Nottingham, Oxford, and
Portsmouth. Using the computerised registers of cooperating
general practitioners,we identified takers of omeprazole in the
period 1993–1995. Records of patients who were still alive and
who had received at least one prescription for omeprazole
were examined and details taken of, inter alia, the patient’s
age, sex, and NHS number, prescription data, and the reasons
for any prescription, together with details of any prior diagno-
sis of malignant disease, any previous upper abdominal surgi-
cal procedures, and any other recorded antisecretory drug use
in the previous 12 months.We excluded from consideration all
those dying prior to the registration date.
Clinical diagnoses were those recorded in individual case
notes and were not re- interpreted, but details of investiga-
tions were recorded. Individual diagnoses of ulcer, oesoph-
agitis, Barrett’s oesophagus, hiatal hernia or reflux, and cancer
required specific mention of these following investigation.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: O/E, observed/expected; PPI, proton pump inhibitor;
NHSCR, National Health Service Central Register; ICD, International
Classification of Disease.
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Records of patients registered were re-examined after two
years, and new diagnoses of oesophageal cancer at hospital
attendance and details of subsequent omeprazole and other
antisecretory drug prescribing were recorded. Patients trans-
ferring to another general practitioner were followed by post
or visit to the practice if nearby. The records of cohort
members were also flagged at the National Health Service
Central Register (NHSCR) in England and Scotland, providing
data on all causes of death and confirmation of cancer
diagnoses.
Observed death rates, classified according to the ninth revis-
ion of the International Classification of Disease (ICD), were
compared with expected population rates in England and
Scotland using published data from the Office of National
Statistics. For this purpose, rates were based on those
individuals dying in 1996, the approximate midpoint of the
study period, taking account of age, within five year groups,
and sex. In addition, death rates were examined in relation to
the number of scripts received by patients for omeprazole, as
noted at the time of registration. Relative risks presented are
the ratios of observed to expected deaths, together with their
95% confidence intervals (CI) throughout, alongside the
observed and expected numbers of deaths.
The study was approved by local ethics committees and by
the Office of National Statistics. It was also constructed to
conform to the guidelines for safety assessment of marketed
medicines (SAMM guidelines),7 and was registered with the
Medicines Control Agency of the UK.
RESULTS
A total of 17 936 patients had been registered by December
1995 when entry was completed, and clinical follow up data
were available after two years in 17 489 (97.5%) patients.
Mean age of the patients at registration was 59.6 years
(median 61.5; range 7–105) with 46.9% being men. In the
year prior to registration, 38% had received 1–2 omeprazole
prescriptions while 25% had received six or more. Table 1
shows the major diagnostic groupings in patients prescribed
omeprazole. Oesophageal disease and gastrointestinal symp-
toms of uncertain cause formed the bulk of the indications.
There were 12 501 diagnoses of oesophageal disease recorded.
Oesophagitis (3664), reflux not otherwise specified (3842),
and hiatal hernia (3142) were the commonest recorded but
with substantial numbers of patients with stricture (791),
ulcer (441), or Barrett’s disease (417) of the oesophagus.
Oesophageal disease was pre-existing cancer in 40 and was
not clearly specified in the remaining 164.
We found that 2096 patients (11.7%) had undergone a total
of 2477 upper abdominal procedures in the past. Commoner
procedures were cholecystectomy (1014 (5.3%)), oesophageal
surgery (489 (2.7%)) and elective ulcer surgery (439 (2.4%)).
Further prescriptions for antisecretory treatments had been
received by 12 703 (72.6%) of 17 489 patients with two year
follow up data; 10 929 (62.5%) had received at least one
further prescription for omeprazole with 8097 having omepra-
zole alone.
Table 2 shows that observed mortality tended to be higher in
the first year after registration and then fell overall to population
Table 1 Major diagnostic groups of patients prescribed omeprazole
% Men
(8409)
% Women
(9527)
% with 6 or more scripts in
year before recruitment*
Oesophageal ulcer 2.8 2.1 39.6
Other oesophageal disease 48.7 49.8 30.3
Gastric ulcer 3.3 3.3 25.9
Other gastric disease 7.6 6.5 24.0
Duodenal ulcer 10.9 5.7 22.3
Other duodenal disease 6.7 3.5 23.7
Gastrointestinal symptoms not otherwise
specified
32.8 37.4 18.9
Prophylaxis 1.0 1.5 27.6
Unclear 3.2 3.3 20.1
Diagnostic figures add up to more than 100% because some patients had more than one diagnosis.
*A single script is equivalent to one month of treatment at a standard dosage.
Table 2 Observed (O) deaths from all causes and observed deaths divided by deaths expected* (O/E) in each study
year
Site n Mean age (y) % Men
Study year
1 2 3 4
All patients
Birmingham 3001 58.3 46.8% O 120 74 86 60
O/E 1.6 1.0 1.1 0.8
Glasgow 3128 58.3 43.7% O 117 89 81 79
O/E 1.3 1.0 0.9 0.9
Newcastle 3514 58.5 48.9% O 143 126 115 74
O/E 1.7 1.5 1.4 0.9
Nottingham 3012 60.6 48.0% O 131 110 107 95
O/E 1.5 1.3 1.2 1.1
Oxford 2318 60.6 45.2% O 76 75 76 57
O/E 1.1 1.1 1.1 0.8
Portsmouth 2963 61.6 48.1% O 137 117 101 108
O/E 1.4 1.2 1.1 1.2
Total 17 936 59.6 46.9% O 724 591 566 473
O/E 1.4 1.2 1.2 1.0
*Expected deaths based on national (England and Wales) rates for 1996, except for Glasgow which is based on Scottish rates for 1996, and total rates
which are based on pooled Scotland, England, and Wales expected deaths. Calculations made for each sex separately within five year age groupings.
Mortality in omeprazole takers 943
www.gutjnl.com
 on 8 November 2007 gut.bmj.comDownloaded from 
expectation, with similar trends in the six conurbations. Table 3
shows the mortality observed for individual ICD chapters by
year, together with their associated relative risks (observed/
expected (O/E)). Mortality was initially higher than expected
for neoplasms (observed 217, expected 119; O/E 1.82; 95% CI
1.58–2.08; p<0.0001) and also for diseases of the circulatory
(observed 284, expected 224; O/E 1.27; 95% CI 1.13–1.43;
p<0.0001), respiratory (observed 112, expected 82; O/E 1.37;
95% CI 1.12–1.64; p<0.001), and digestive (observed 45,
expected 18; O/E 2.56; 95% CI 1.87–3.43; p<0.0001) systems.
Death rates from neoplasms fell to population expectation by
year 4, as did those for the circulatory and respiratory systems.
Greater mortality than expected was also initially recorded for
infectious and parasitic disease (O/E 3.09; 95% CI 1.33–6.08;
p<0.01), falling to population expectation by the fourth year of
the study. Initially increased mortality from musculoskeletal
disorders, upper gastrointestinal disorders, and chronic liver
disease, although falling with time towards population expecta-
tion, still tended to remain raised.
Table 4 shows the observed and expected deaths for selected
ICD rubrics, including major gut epithelial cancers and cancer
of the lung, breast, and blood forming tissues, ischaemic and
cerebrovascular disease, and upper gastrointestinal causes. For
all selected causes, initial increases in mortality declined
towards or below population expectation, except for oesopha-
geal cancer and liver disease which remained significantly
above expectation.
To examine results for oesophageal cancer inmore detail,we
stratified data in those without oesophageal cancer at
registration according to whether patients were recorded ini-
tially as having Barrett’s disease, oesophageal ulcer, stricture,
or oesophagitis (categorised as severe disease), or whether
they had reflux or hiatal hernia without Barrett’s disease,
ulcer, stricture, or oesophagitis (categorised as mild disease).
Table 5 shows the types of non-malignant oesophageal disease
present in the 38 patients diagnosed as having oesophageal
cancer after registration. Among those with severe oesopha-
geal disease, 27 died of oesophageal cancer (expectation 8.2 in
four years; O/E 3.30; 95% CI 2.17–4.80). In contrast, of those
with mild oesophageal disease, evidenced by clinical diag-
noses of reflux or hiatal hernia, only six died of oesophageal
cancer (expectation 5.9; O/E 1.02; 95% CI 0.37–2.22). In those
without initial clinical diagnoses of oesophageal disease, five
patients died (against expectation 6.5; O/E 0.77; 95% CI 0.25–
1.80). Of the 417 who had Barrett’s disease identified at some
time and recorded at registration, nine had died of oesopha-
geal cancer (O/E 11.25; 95% CI 5.14–21.36).
In those with severe oesophageal disease, the risk of devel-
oping oesophageal cancer was slightly lower (observed 8,
expected 2.8; O/E 2.86; 95% CI 1.23–5.63) in those who had
received six or more scripts in the year before registration than
in those who had received fewer (observed 19, expected 5.2;
O/E 3.65; 95% CI 2.20–5.71). Examination of mortality from
all other neoplasms, and from all other (non-neoplastic)
Table 3 Observed and expected number of deaths for individual ICD (International Classification of Disease) chapters
Study year
Exp/year1 2 3 4
001–139 Infectious/parasitic diseases 8 (3.1)* 4 (1.5) 2 (0.8) 2 (0.8) 3
140–239 Neoplasms 217 (1.8)* 160 (1.3)* 147 (1.2)* 116 (1.0) 119
240–279 Endocrine, nutritional 7 (1.1) 7 (1.1) 5 (0.8) 10 (1.6) 6
280–289 Blood disorders 1 (0.6) 1 (0.6) 1 (0.6) 3 (1.7) 2
290–319 Mental disorders 5 (0.5) 8 (0.9) 6 (0.6) 5 (0.5) 9
320–389 Nervous system 4 (0.5) 5 (0.7) 7 (0.9) 5 (0.7) 8
390–459 Circulatory system 284 (1.3)* 237 (1.1) 251 (1.1)* 190 (0.9)* 224
460–519 Respiratory system 112 (1.4)* 93 (1.1) 87 (1.1) 80 (1.0) 82
520–579 Digestive system 45 (2.6)* 35 (2.0)* 35 (2.0)* 28 (1.6)* 18
580–629 Genitourinary system 11 (1.7) 11 (1.7) 7 (1.1) 8 (1.2) 7
680–709 Skin/subcutaneous tissue 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1
710–739 Musculoskeletal system 8 (2.6)* 5 (1.6) 6 (1.9) 10 (3.2)* 3
740–759 Congenital anomalies 0 (0.0) 1 (2.3) 2 (4.7) 0 (0.0) 0
780–799 Symptoms/ill defined 10 (1.1) 13 (1.5) 5 (0.6) 11 (1.2) 9
800–999 Injury and poisoning 10 (1.1) 11 (1.2) 6 (0.6) 11 (1.2) 9
Total 722 591 567 479 500
Observed/expected (O/E) ratios in parentheses.
*O/E significantly >1.0, p<0.05.
Table 4 Observed and expected number of deaths for selected ICD (International Classification of Disease) rubrics
All patients
Study year
Exp/year1 2 3 4
150.0–150.9 Malignant neoplasm, oesophagus 36 (6.9)* 17 (3.3)* 8 (1.6) 15 (2.9)* 5.2
151.0–151.9 Malignant neoplasm, stomach 25 (6.1)* 15 (2.5)* 7 (1.2) 4 (0.9) 5.9
153.0–154.1 Malignant neoplasm, colon and rectum 19 (1.4) 20 (1.5) 19 (1.4) 12 (0.9) 13.6
162.0–162.9 Malignant neoplasm, trachea and lung 45 (1.6) 33 (1.2) 36 (1.3) 28 (1.0) 27.6
174.0–174.9 Malignant neoplasm, female breast 11 (1.1) 15 (1.5) 11 (1.1) 9 (0.9) 9.8
200.0–208.0 Lymphoma, myeloma, leukaemia 15 (1.9)* 12 (1.5) 16 (2.1)* 6 (0.8) 7.8
410.0–414.9 Ischaemic heart disease 169 (1.4)* 142 (1.2)* 143 (1.2)* 108 (0.9) 119.3
430–438 Cerebrovascular disease 64 (1.1) 56 (1.0) 59 (1.0) 41 (0.7) 58.8
530–537.9 Disease of oesophagus, stomach, and
duodenum, and GI haemorrhage
10 (2.2)* 13 (2.9)* 10 (2.2)* 5 (1.1) 4.5
571–571.9 Chronic liver disease and cirrhosis 16 (6.0)* 11 (4.1)* 7 (2.6)* 7 (2.6)* 2.7
Total 410 334 316 235 255.1
Observed/expected (O/E) ratios in parentheses.
*O/E significantly >1.0, p<0.05.
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causes, likewise showed no relationship with the intensity of
treatment. Clear histological diagnoses were available in 29 of
38 oesophageal cancer cases diagnosed after the study enrol-
ment date. Fifteen (83%) of 18 patients with adenocarcino-
mata had initial clinical diagnoses of oesophagitis, oesopha-
geal ulcer, stricture, and/or Barrett’s oesophagus. In contrast,
only five (45%) of 11 patients with squamous cancers had
such initial diagnoses (p=0.086, Fisher’s exact test).
DISCUSSION
By registering patients with the NHSCR, we systematically
collected information on the causes of death over four years in
nearly 18 000 patients prescribed omeprazole. Mortality was
significantly greater than population expectation in the first
year after registration, falling progressively to that expectation
by the fourth year. Increased mortality in the first year is
unlikely to reflect drug effects because it was detectable for a
wide variety of causes and was unrelated to the duration of
initial treatment. Furthermore, very similar patterns were
observed in our previous studies of cimetidine takers
conducted in the same way.5 6 We deduce therefore that
confounding by indication for treatment explains the general
patterns observed. Thus treatment of chest pain attributed to
reflux, but actually anginal in origin, could well explain
increased cardiovascular disease mortality. Use of omeprazole
in those perceived to be at high risk of ulcer complications is
also likely to explain raised risks of death from peptic ulcer
disease and musculoskeletal disease.8 This finding should not
be taken to imply that such treatment fails in its objectives:
there is strong evidence from controlled trials to indicate that
treatment is appropriate and successful.9–11 In the same way,
increased mortality from musculoskeletal diseases seems
likely to reflect use of omeprazole in those perceived as at risk
of ulcer complications.12 The increased mortality observed
from infectious and parasitic disease in the first two years of
observation lacks a plausible explanation but may represent
the play of chance in small numbers. PPI use is known to be
associated with an increased frequency of dysenteric infec-
tions but not with death from this cause.13 14 Persistently
increased mortality from chronic liver disease in our cohort
seems likely to represent deaths in patients with upper
gastrointestinal symptoms coincident liver disease, and
common epidemiological features in smoking and
drinking.15 16 Scrutiny of our cases revealed none where a
causal relationship with antisecretory treatment seemed
likely. Prescribing of omeprazole to attendees at general prac-
titioner surgeries with other main complaints, a form of Berk-
son’s bias,17 would be expected to lead to increases in mortality
from a broad range of complaints, particularly in the early
period after prescription, a phenomenon seen in our previous
studies of cimetidine.
Examination of the data for neoplastic diseases showed that
mortality increases were particularly high for gastric and
oesophageal cancer in the first year after registration. This
almost certainly represents confounding by indication rather
than an adverse drug effect, or masking of disease by
treatment. The patterns are similar to those seen with cimeti-
dine; no dose relationship was seen with treatment, and death
rates fell progressively with time. Persisting increases into the
fourth year were only seen for oesophageal cancer. The major-
ity of those dying with oesophageal cancer had initial
diagnoses suggesting severe oesophageal disease, namely Bar-
rett’s disease, stricture, ulcer, or oesophagitis. Observed
mortality was more than three times as great as expected in
these patients whereas it was not increased in those with ini-
tial diagnoses of hiatal hernia or reflux, or in those initially
considered to have disease outside the oesophagus as the rea-
son for omeprazole prescription. Patients with adenocarcino-
mata were six times as likely to have initial clinical diagnoses
suggesting severe underlying oesophageal disease as those
with squamous tumours. Observed mortality was more than
10 times as high in patients in whom Barrett’s disease had
been detected at some time in their clinical course whether or
not found at registration. However, findings of high propor-
tions of Barrett’s disease in this group may reflect the results
of differences in intensity of surveillance in those with and
without malignant disease.
Although in the long term follow up of approximately
10 000 patients prescribed cimetidine we found no evidence
that treatment was likely to cause gastric or other varieties of
gastrointestinal cancer,4–6 it has recently been suggested that
histamine receptor antagonist treatment might predispose to
cardio-oesophageal adenocarcinoma .18 That claim was based
on comparing prior drug intake in cardio-oesophageal cancer
patients with that in individuals with myocardial infarction.
The nature of the control would seem to make sensible deduc-
tions about causation impossible. Our findings indicate
strongly that the nature of the underlying oesophageal disease
is the major, and probably sole, cause of the raised risk of
oesophageal cancer death in our omeprazole takers. This con-
clusion is reinforced by evidence that death rates were
unrelated to the number of omeprazole scripts received at
registration. This finding is consonant with findings that the
proportions of patients receiving acid suppressant therapy for
Barrett’s oesophagus, and oesophagitis without Barrett’s
disease, did not differ significantly.19 The data in our study
suggest strongly that underlying oesophageal disease explains
the increased risk of oesophageal cancer but it should be noted
that classification depended upon reports available to us in
practice case records, these not being produced to standard-
ised criteria. The actual strength of risk is therefore uncertain.
Systematic study has suggested that there may be publication
bias in the reporting of cancer risks in Barrett’s oesophagus.20
Our data show, compared with the findings of others, rather
moderate increases in the risk of oesophageal cancer. Our set
has particular strengths. Firstly, patients for study were
selected prior to the outcomes being known. Secondly, the
Table 5 Observed and expected deaths from cancer of the oesophagus in successive years according to initial
oesophageal disease diagnosis in those cancer free at registration
Initial oesophageal diagnosis
Expected
No/year
Observed by year
O/E (95% CI)1 2 3 4 Total
Barrett’s disease/ulcer/stricture/oesophagitis (n=5517) 2.0 7 5 6 9 27 3.30 (2.17–4.80)
(Barrett’s disease cases only)* (n=417) (0.2) (2) (1) (3) (3) (9) 11.25 (5.14–21.36)
Hiatal hernia or reflux only (n=6984) 1.5 1 1 1 3 6 1.02 (0.37–2.22)
No oesophageal diagnosis (n=5435) 1.6 3 1 1 0 5 0.77 (0.25–1.80)
Total 5.2 11 7 8 12 38 1.85 (1.31–2.54)
O/E, observed/expected.
*Includes all diagnoses of the condition, irrespective of date of diagnosis.
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population studied was large, and the follow up prolonged and
complete. Thirdly, the number of incident oesophageal
tumours diagnosed after enrolment (38) was large.
It has been suggested that, based on symptoms alone,
patients with oesophageal reflux are at nearly eight fold
increased risk of adenocarcinoma.21 Our data indicate that in
our population, any increase in oesophageal cancer risk may
be confined to those with evidence of mucosal structural
damage, and that simple symptomatic reflux may not pose
significant risks. This conclusion is consonant with that of
Cohen and Parkman22 that structural damage, and Barrett’s
oesophagus in particular, are the critical factors. Our data
showing a fall in gastric cancer death rates by the fourth year
of the study to slightly below population expectation suggest
that gastric cancer risk is neither intrinsically raised in the
population studied nor influenced in the period under review
by omeprazole or other antisecretory drug prescribing. Our
results are reassuring given concern that treatment might
cause early gastric atrophy,23 24 although any increased
incidence of gastric atrophy associated with antisecretory
treatment might take longer than the period under review to
influence mortality from gastric cancer. We conclude that
treatment with omeprazole per se did not increase the risks of
dying from general or neoplastic disease.Our data also suggest
that raised risks of oesophageal malignancy are associated
with underlying severe oesophageal disease.
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